共 68 条
[1]
Johnson RH(2013)Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009 JAMA 309 800-805
[2]
Chien FL(2012)Breast cancer incidence trends in European women aged 20–39 years at diagnosis Breast Cancer Res Treat 134 363-370
[3]
Bleyer A(2015)Fertility preservation options in breast cancer patients Gynecol Endocrinol 31 846-851
[4]
Merlo DF(2017)The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review Hum Reprod 32 1033-1045
[5]
Ceppi M(2006)Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy J Clin Endocrinol Metab 91 3885-3890
[6]
Filiberti R(2020)Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial Zhonghua Fu Chan Ke Za Zhi 55 9-14
[7]
Bocchini V(2013)Luteal-phase ovarian stimulation case report: three-year follow-up of a twin birth J Fertiliz. 1 106-132
[8]
Znaor A(2021)Incidences and risk factors of moderate-to-severe ovarian hyperstimulation syndrome and severe hemoperitoneum in 1,435,108 oocyte retrievals Reprod Biomed Online 42 125-707
[9]
Gamulin M(2014)Severe haematoperitoneum caused by ovarian bleeding after transvaginal oocyte retrieval: a retrospective analysis and systematic literature review Reprod Biomed Online 29 699-undefined
[10]
Kasum M(2020)The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study J Gynecol Obstet Hum Reprod 49 101643-undefined